Liraglutide prevents fast weight gain and βWuhan, Hubei-cell dysfunction in male catch-up growth rats

Experimental Biology and Medicine

Volumn 240, Issue 9, 2015, Pages 1165-1176

  Zheng, Juan ^a,b   Chen, Ting ^a,c   Zhu, Ying ^a   Li, Hui Qing ^a   Deng, Xiu Ling ^a   Wang, Qing Hua ^b,d   Zhang, Jiao Yue ^a   Chen, Lu Lu ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c CHILDREN S HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Catch up growth; GLP 1; Liraglutide; cell dysfunction

Indexed keywords

CASPASE 3; EXENDIN 9 39; FATTY ACID; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN; LIRAGLUTIDE; PROCASPASE 3; PROTEIN BCL 2; TRANSCRIPTION FACTOR PDX 1; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; HOMEODOMAIN PROTEIN; INCRETIN; PANCREATIC AND DUODENAL HOMEOBOX 1 PROTEIN; TRANSACTIVATOR PROTEIN;

ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD ANALYSIS; BODY WEIGHT; CALORIC INTAKE; CATCH UP GROWTH; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FAT MASS; GLUCOSE METABOLISM; HYPERGLYCEMIC CLAMP TECHNIQUE; IMMUNOHISTOCHEMISTRY; INSULIN RELEASE; LIPID METABOLISM; LIPID STORAGE; MALE; MORPHOMETRICS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL DYSFUNCTION; PANCREAS ISLET DISEASE; PROTEIN EXPRESSION; RADIOIMMUNOASSAY; RAT; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; WEIGHT GAIN; WESTERN BLOTTING; ADVERSE EFFECTS; ANIMAL; ANIMAL MODEL; BLOOD; CALORIC RESTRICTION; CELL PROLIFERATION; CELL SURVIVAL; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GENETICS; METABOLISM; OBESITY, ABDOMINAL; PANCREAS ISLET BETA CELL; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SECRETION (PROCESS); SPRAGUE DAWLEY RAT; UPREGULATION;

ANIMALS; CALORIC RESTRICTION; CELL PROLIFERATION; CELL SURVIVAL; DIABETES MELLITUS, TYPE 2; FATTY ACIDS, NONESTERIFIED; HOMEODOMAIN PROTEINS; HYPOGLYCEMIC AGENTS; INCRETINS; INSULIN; INSULIN-SECRETING CELLS; LIRAGLUTIDE; MALE; MODELS, ANIMAL; OBESITY, ABDOMINAL; RATS; RATS, SPRAGUE-DAWLEY; TRANS-ACTIVATORS; TRIGLYCERIDES; UP-REGULATION; WEIGHT GAIN;

EID: 84960463799     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1177/1535370214567614     Document Type: Article

References (55)

1. Drucker DJ. The biology of incretin hormones. Cell Metab 2006;3:153–65
2. MacDonald PE, El-kholy W, Riedel MJ, Salapatek AMF, Light PE, Wheeler MB. The multiple actions of GLP-1 on the process of glucosestimulated insulin secretion. Diabetes 2002;51:S434–42
3. Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci USA 1987;84:3434–8
4. Alarcon C, Wicksteed B, Rhodes CJ. Exendin 4 controls insulin production in rat islet beta cells predominantly by potentiation of glucosestimulated proinsulin biosynthesis at the translational level. Diabetologia 2006;49:2920–9
5. Drucker DJ. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol Endocrinol 2003;17:161–71
6. Buteau J, Foisy S, Joly E, Prentki M. Glucagon-like peptide 1 induces pancreatic b-cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes 2003;52:124–32
7. Wang Q, Brubaker P. Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia 2002;45:1263–73
8. Farilla L, Bulotta A, Hirshberg B, Calzi SL, Khoury N, Noushmehr H, Bertolotto C, Mario UD, Harlan DM, Perfetti R. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003;144:5149–58
9. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696–705
10. Wang D, Luo P, Wang Y, Li W, Wang C, Sun D, Zhang R, Su T, Ma X, Zeng C,Wang H, Ren J, Cao F. Glucagon-like peptide-1 protects against cardiac microvascular injury in diabetes via a cAMP/PKA/Rhodependent mechanism. Diabetes 2013;62:1697–708
11. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39–47
12. Yoon KH, Lee JH, Kim JW, Cho JH, Choi YH, Ko SH, Zimmet P, Son HY. Epidemic obesity and type 2 diabetes in Asia. Lancet 2006;368:1681–8
13. Park S, Park CH, Jang JS. Antecedent intake of traditional Asian-style diets exacerbates pancreatic b-cell function, growth and survival after Western-style diet feeding in weaning male rats. J Nutr Biochem 2006;17:307–18
14. Ong KK, Ahmed ML, Emmett PM, Preece MA, Dunger DB. Association between postnatal catch-up growth and obesity in childhood: prospective cohort study. BMJ 2000;320:967–71
15. Prader A, Tanner JM, Von Harnack GA. Catch-up growth following illness or starvation: an example of developmental canalization in man. J Pediatr 1963;62:646–59
16. Victora CG, Barros FC. Commentary: the catch-up dilemma—relevance of Leitch’s ‘low–high’ pig to child growth in developing countries. Int J Epidemiol 2001;30:217–20
17. Barker DJP, Hales CN, Fall CHD, Osmond C, Phipps K, Clark PMS. Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth. Diabetologia 1993;36:62–67
18. Rotteveel J, van Weissenbruch MM, Twisk JW, Delemarre-Van WHA. Infant and childhood growth patterns, insulin sensitivity, and blood pressure in prematurely born young adults. Pediatrics 2008;122:313–21
19. Dulloo AG. Regulation of fat storage via suppressed thermogenesis: a thrifty phenotype that predisposes individuals with catch-up growth to insulin resistance and obesity. Horm Res Paediatr 2008;65:90–97
20. Chen LL, Hu X, Zheng J, Kong W, Zhang HH, Yang WH, Zhu SP, Zeng TS, Zhang JY, Deng XL, Hu D. Lipid overaccumulation and drastic insulin resistance in adult catch-up growth rats induced by nutrition promotion after undernutrition. Metabolism 2011;60:569–78
21. Chen LL, Yang WH, Zheng J, Hu X, Kong W, Zhang HH. Research effect of catch-up growth after food restriction on the entero-insular axis in rats. Nutr Metab (Lond) 2010;7:45
22. Chen LL, Yang WH, Zheng J, Zhang JY, Yue L. Influence of catch-up growth on islet function and possible mechanisms in rats. Nutrition 2011;27:456–62
23. Soltani N, Qiu H, Aleksic M, Glinka Y, Zhao F, Liu R, Li Y, Zhang N, Chakrabarti R, Ng T, Jin T, Zhang H, Lu W, Feng Z, Prud’homme G, Wang Q. GABA exerts protective and regenerative effects on islet beta cells and reverses diabetes. Proc Natl Acad Sci USA 2011;108:11692–7
24. Henquin JC, Nenquin M, Stiernet P, Ahren B. In vivo and in vitro glucose- induced biphasic insulin secretion in the mouse pattern and role of cytoplasmic Ca2þ and amplification signals in b-cells. Diabetes 2006;55:441–51
25. MacDonald PE, Joseph JW, Yau D, Diao J, Asghar Z, Dai F, Oudit GY, Patel MM, Backx PH, Wheeler MB. Impaired glucose-stimulated insulin secretion, enhanced intraperitoneal insulin tolerance, and increased bcell mass in mice lacking the p110g isoform of phosphoinositide 3- kinase. Endocrinology 2004;145:4078–83
26. Ferrannini E, Mari A. Beta cell function and its relation to insulin action in humans: a critical appraisal. Diabetologia 2004;47:943–56
27. Bouwens L, Rooman I. Regulation of pancreatic beta-cell mass. Physiol Rev 2005;85:1255–70
28. Tourrel C, Bailbe D, Meile MJ, Kergoat M, Portha B. Glucagon-like peptide-1 and exendin-4 stimulate b-cell neogenesis in streptozotocintreated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes 2001;50:1562–70
29. Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased betacell mass and improved glucose tolerance in diabetic rats. Diabetes 1999;48:2270–6
30. Garber AJ. Long-acting glucagon-like peptide 1 receptor agonists. A review of their efficacy and tolerability. Diabetes Care 2011;34:S279–84
31. Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 2009;5:262–9
32. Chan CB, MacPhail RM, Sheu L, Wheeler MB, Gaisano HY. Beta-cell hypertrophy in fa/fa rats is associated with basal glucose hypersensitivity and reduced SNARE protein expression. Diabetes 1999;48:997–1005
33. Laybutt DR, Glandt M, Xu G, Ahn YB, Trivedi N, Bonner-Weir S, Weir GC. Critical reduction in b-cell mass results in two distinct outcomes over time adaptation with impaired glucose tolerance or decompensated diabetes. J Biol Chem 2003;278:2997–3005
34. Weir GC, Bonner-Weir S. Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes 2004;53:S16–21
35. Rieck S, Kaestner KH. Expansion of b-cell mass in response to pregnancy. Trends Endocrinol Metab 2010;21:151–8
36. Saisho Y, Butler AE, Manesso E, Elashoff D, Rizza RA, Butler PC. b-Cell mass and turnover in humans effects of obesity and aging. Diabetes Care 2013;36:111–7
37. Donath MY, Ehses JA, Maedler K, Schumann DM, Ellingsgaard H, Eppler E, Reinecke M. Mechanisms of b-cell death in type 2 diabetes. Diabetes 2005;54:S108–13
38. Wang Q, Li L, Xu E, Wong V, Rhodes C, Brubaker PL. Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells. Diabetologia 2004;47:478–87
39. Elghazi L, Balcazar N, Bernal-Mizrachi E. Emerging role of protein kinase B/Akt signaling in pancreatic b-cell mass and function. Int J Biochem Cell Biol 2006;38:689–95
40. Jonsson J, Carlsson L, Edlund T, Edlund H. Insulin-promoter-factor 1 is required for pancreas development in mice. Nature 1994;371:606–9
41. Stoffers DA, Zinkin NT, Stanojevic V, Clarke WL, Habener JF. Pancreatic agenesis attributable to a single nucleotide deletion in the human IPF1 gene coding sequence. Nat Genet 1997;15:106–10
42. Habener JF, Stoffers DA. A newly discovered role of transcription factors involved in pancreas development and the pathogenesis of diabetes mellitus. Proc Natl Acad Sci USA 1997;110:12–21
43. Perfetti R, Zhou JIE, Doyle ME, Egan JM. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 2000;141:4600–5
44. Buteau J, Roduit R, Susini S, Prentki M. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (Pdx-1) DNA binding activity in beta (INS-1)-cells. Diabetologia 1999;42:856–64
45. Li Y, Cao X, Li LX, Brubaker PL, Edlund H, Drucker DJ. b-Cell Pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1. Diabetes 2005;54:482–91
46. Larsen PJ, Fledelius C, Knudsen LB, Tang-Christensen M. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes 2001;50:2530–9
47. Ryan GJ, Foster KT, Jobe LJ. Review of the therapeutic uses of liraglutide. Clin Ther 2011;33:793–811
48. Manning S, Pucci A, Finer N. Pharmacotherapy for obesity: novel agents and paradigms. Ther Adv Chronic Dis 2014;5:135–48
49. Gerich JE. Is reduced first-phase insulin release the earliest detectable abnormality in individuals destined to develop type 2 diabetes? Diabetes 2002;51:S117–21
50. Jimenez-Chillaron JC, Hernandez-Valencia M, Reamer C, Fisher S, Joszi A, Hirshman M, Oge A, Walrond S, Przybyla R, Boozer C, Goodyear LJ, Patti ME. b-Cell secretory dysfunction in the pathogenesis of low birth weight-associated diabetes: a murine model. Diabetes 2005;54:702–11
51. Casimir M, de Andrade PB, Gjinovci A, Montani JP, Maechler P, Dulloo AG. A role for pancreatic beta-cell secretory hyperresponsiveness in catch-up growth hyperinsulinemia: relevance to thrifty catch-up fat phenotype and risks for type 2 diabetes. Nut Metab (Lond) 2011;8:2
52. Yaney GC, Corkey BE. Fatty acid metabolism and insulin secretion in pancreatic beta cells. Diabetologia 2003;46:1297–312
53. Pi J, Zhang Q, Fu J, Woods CG, Hou Y, Corkey BE, Collins S, Andersen ME. ROS signaling, oxidative stress and Nrf2 in pancreatic beta-cell function. Toxicol Appl Pharmacol 2010;244:77–83
54. Newsholme P, Haber EP, Hirabara SM, Rebelato ELO, Procopio J, Morgan D, Oliveira-Emilio HC, Carpinelli AR, Curi R. Diabetes associated cell stress and dysfunction: role of mitochondrial and nonmitochondrial ROS production and activity. J Physiol 2007;583:9–24
55. Sisley S, Gutierrez-Aguilar R, Scott M, D’Alessio DA, Sandoval DA, Seeley RJ. Neuronal GLP1R mediates liraglutide’s anorectic but not glucose-lowering effect. J Clin Invest 2014;124:2456–63